Aardvark therapeutics reports full year 2024 financial results and provides business highlights

San diego, march 31, 2025 (globe newswire) -- aardvark therapeutics, inc. (aardvark) (nasdaq: aard), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended december 31, 2024, and provided business highlights.
AARD Ratings Summary
AARD Quant Ranking